We have located links that may give you full text access.
Disparities in Study Inclusion and Screening Rates in Breast Cancer Screening Rates among Transgender People: A Systematic Review.
Journal of the American College of Radiology : JACR 2024 April 24
BACKGROUND: Breast cancer screening trends of transgender and gender diverse (TGD) people remain largely unknown. This is concerning, as data is necessary to inform recommendations made by clinicians to their patients and by national guidelines to clinicians. The aim of this review is to explore the state of existing research literature and provide a summary report of current breast cancer screening rates in TGD adults.
METHODS: All articles were identified using Medical Subject Headings (MeSH) terms Inclusion criteria were all the following: 1) Documents inclusion of at least one participant who identifies as a TGD person; 2) At least one TGD participant with top-surgery or currently receiving estrogen-based gender affirming hormone therapy (GAHT); 3) Results report rates of breast cancer screening or mammogram referral.
RESULTS: Twelve articles met inclusion criteria, six cross-sectional studies and six retrospective chart reviews. Three studies conducted secondary analysis of the Behavioral Risk Factor Surveillance System (BRFSS) national dataset, and nine articles recruited their own sample with TGD participant ranges from 30 to 1,822 and cisgender women ranges from 242 to 18,275. Three studies found lower rates of screening in transfeminine persons receiving gender-affirming care compared to cisgender women; two studies found lower rates among TGD people compared to cisgender women; and three studies found no differences between the breast cancer screening rates of TGD and cisgender participants.
CONCLUSION: Limited studies recruit and report trends in breast cancer screening of TGD people. Those that do include TGD participants have mixed results, but overall TGD people had lower rates of breast cancer screening. More research is needed regarding breast cancer screening of TGD people to inform the development of protocols that ensure equitable access to preventative care.
METHODS: All articles were identified using Medical Subject Headings (MeSH) terms Inclusion criteria were all the following: 1) Documents inclusion of at least one participant who identifies as a TGD person; 2) At least one TGD participant with top-surgery or currently receiving estrogen-based gender affirming hormone therapy (GAHT); 3) Results report rates of breast cancer screening or mammogram referral.
RESULTS: Twelve articles met inclusion criteria, six cross-sectional studies and six retrospective chart reviews. Three studies conducted secondary analysis of the Behavioral Risk Factor Surveillance System (BRFSS) national dataset, and nine articles recruited their own sample with TGD participant ranges from 30 to 1,822 and cisgender women ranges from 242 to 18,275. Three studies found lower rates of screening in transfeminine persons receiving gender-affirming care compared to cisgender women; two studies found lower rates among TGD people compared to cisgender women; and three studies found no differences between the breast cancer screening rates of TGD and cisgender participants.
CONCLUSION: Limited studies recruit and report trends in breast cancer screening of TGD people. Those that do include TGD participants have mixed results, but overall TGD people had lower rates of breast cancer screening. More research is needed regarding breast cancer screening of TGD people to inform the development of protocols that ensure equitable access to preventative care.
Full text links
Related Resources
Trending Papers
Executive Summary: State-of-the-Art Review: Unintended Consequences: Risk of Opportunistic Infections Associated with Long-term Glucocorticoid Therapies in Adults.Clinical Infectious Diseases 2024 April 11
Clinical practice guidelines on the management of status epilepticus in adults: A systematic review.Epilepsia 2024 April 13
Autoimmune Hemolytic Anemias: Classifications, Pathophysiology, Diagnoses and Management.International Journal of Molecular Sciences 2024 April 13
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app